Disease and patient characteristics according to the type of sAML (n = 2000)
| Characteristic . | MDS-AML . | MDS/MPN-AML . | MPN-AML . | t-AML . | neo-AML . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | ||
| Global | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Age, y | 70 (19-97) | 883 (100) | 69 (31-92) | 208 (100) | 68 (31-92) | 225 (100) | 67 (18-104) | 502 (100) | 73 (26-93) | 179 (100) | <.001* |
| Gender | 882 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Male | 548 (62) | 148 (71) | 129 (57) | 248 (49) | 121 (68) | <.001 | |||||
| Female | 334 (38) | 61 (29) | 97 (43) | 254 (51) | 58 (32) | ||||||
| ECOG | 1 (0-4) | 670 (100) | 1 (0-4) | 165 (100) | 1 (0-4) | 188 (100) | 1 (0-4) | 435 (100) | 1 (0-4) | 169 (100) | <.001* |
| 0 | 185 (28) | 34 (21) | 39 (21) | 130 (30) | 40 (24) | <.001 | |||||
| 1 | 268 (40) | 62 (38) | 73 (39) | 178 (41) | 64 (38) | ||||||
| 2 | 139 (21) | 36 (22) | 35 (19) | 80 (18) | 44 (26) | ||||||
| 3 | 67 (10) | 25 (15) | 27 (14) | 38 (9) | 18 (11) | ||||||
| 4 | 11 (2) | 8 (5) | 14 (7) | 9 (2) | 3 (2) | ||||||
| FAB subtype | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| M0/M6/M7 | 80 (9) | 4 (2) | 42 (19) | 65 (13) | 22 (12) | <.001 | |||||
| M1/M2 | 230 (26) | 18 (9) | 30 (13) | 118 (24) | 51 (28) | ||||||
| M4/M5 | 100 (11) | 79 (38) | 15 (7) | 121 (24) | 54 (30) | ||||||
| Not available | 474 (54) | 108 (52) | 139 (61) | 198 (39) | 52 (29) | ||||||
| Hepatosplenomegaly | 419 (100) | 114 (100) | 112 (100) | 290 (100) | 142 (100) | <.001 | |||||
| Yes | 77 (18) | 37 (32) | 44 (39) | 52 (18) | 24 (17) | ||||||
| No | 342 (82) | 77 (68) | 68 (61) | 238 (82) | 118 (83) | ||||||
| WBC, ×109/L | 4.4 (0.1-310.4) | 786 (100) | 23.5 (0.1-300.2) | 169 (100) | 10.8 (0.3-312) | 198 (100) | 5.1 (0.1-289) | 466 (100) | 10.7 (0.-230.7) | 173 (100) | <.001* |
| Hemoglobin, g/dL | 8.9 (3.3-17.2) | 690 (100) | 9.1 (4-15.1) | 154 (100) | 8.7 (4.7-15) | 173 (100) | 9.1 (3.2-15.2) | 452 (100) | 9.1 (4.4-14.4) | 170 (100) | .23* |
| Platelet count, ×109/L | 45 (1-1645) | 691 (100) | 55 (6-459) | 155 (100) | 74 (1-1372) | 173 (100) | 47 (2-1442) | 456 (100) | 58 (5-462) | 171 (100) | <.001* |
| BM blasts, % | 36 (2-100) | 653 (100) | 40 (1-100) | 136 (100) | 35 (0-94) | 148 (100) | 55 (0-100) | 408 (100) | 58 (10-100) | 160 (100) | <.001* |
| Creatinine, mg/dL | 0.97 (0.32-9.2) | 500 (100) | 1.07 (0.29-7.2) | 133 (100) | 0.95 (0.25-5.09) | 141 (100) | 0.9 (0.07-5.48) | 416 (100) | 0.97 (0.4-8.5) | 163 (100) | <.001* |
| Urea, mg/dL | 38 (4-192) | 456 (100) | 44 (11-255) | 121 (100) | 39 (8-242) | 126 (100) | 35 (2-243) | 391 (100) | 41 (11-267) | 146 (100) | <.001* |
| Uric acid, mg/dL | 5 (0.1-19) | 413 (100) | 6.5 (0.1-17.1) | 119 (100) | 5.8 (0-16.2) | 121 (100) | 4.9 (0-14.4) | 366 (100) | 5.3 (0-13) | 143 (100) | <.001* |
| Bilirubin, mg/dL | 0.7 (0.14-7.5) | 449 (100) | 0.75 (0.22-7) | 127 (100) | 0.67 (0.2-5.5) | 137 (100) | 0.64 (0.07-9.94) | 392 (100) | 0.62 (0.1-4.57) | 151 (100) | .06* |
| AST, U/L | 22 (7-171) | 451 (100) | 22 (6-496) | 119 (100) | 23 (8-151) | 124 (100) | 22 (5-213) | 383 (100) | 21 (8-338) | 150 (100) | .81* |
| ALT, U/L | 18 (2-272) | 461 (100) | 16 (3-515) | 121 (100) | 18 (3-160) | 131 (100) | 20 (3-623) | 395 (100) | 19 (5-328) | 152 (100) | .24* |
| AP, U/L | 78 (29-702) | 412 (100) | 82 (14-1158) | 115 (100) | 80 (26-1525) | 120 (100) | 77 (19-3571) | 354 (100) | 75 (2-3402) | 143 (100) | .41* |
| Albumin, g/dL | 3.7 (2.1-7) | 389 (100) | 3.7 (1.7-5.8) | 113 (100) | 3.7 (1.9-5.2) | 117 (100) | 3.7 (1.8-5.8) | 340 (100) | 3.7 (2.6-4.9) | 136 (100) | .95* |
| LDH, U/L | 416 (13-9168) | 571 (100) | 612 (96-11380) | 138 (100) | 768 (102-10560) | 147 (100) | 436 (12-9540) | 398 (100) | 561 (112-13420) | 149 (100) | <.001* |
| Fibrinogen, mg/dL | 423 (1-1033) | 358 (100) | 410 (1-940) | 111 (100) | 467 (3-889) | 115 (100) | 422 (3-983) | 328 (100) | 444 (2-1500) | 137 (100) | .04* |
| Cytogenetics | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Normal | 247 (28) | 61 (29) | 49 (22) | 107 (21) | 60 (34) | <.001 | |||||
| Abnormal | 361 (41) | 72 (34) | 102 (45) | 266 (53) | 74 (41) | ||||||
| No metaphases | 65 (7) | 10 (5) | 12 (5) | 45 (9) | 14 (8) | ||||||
| Not available | 211 (24) | 66 (32) | 63 (28) | 84 (17) | 31 (17) | ||||||
| MRC cytogenetic risk | 612 (100) | 134 (100) | 152 (100) | 382 (100) | 137 (100) | ||||||
| Favorable | 4 (1) | 1 (1) | 2 (1) | 31 (8) | 11 (8) | <.001 | |||||
| Intermediate | 377 (62) | 94 (70) | 64 (42) | 172 (45) | 88 (64) | ||||||
| Adverse | 231 (38) | 38 (28) | 86 (57) | 179 (47) | 38 (28) | ||||||
| FLT3-ITD | 340 (100) | 104 (100) | 86 (100) | 288 (100) | 114 (100) | ||||||
| Positive | 35 (10) | 11 (11) | 3 (3) | 26 (9) | 24 (21) | <.001 | |||||
| Negative | 305 (90) | 93 (89) | 83 (97) | 262 (91) | 90 (79) | ||||||
| NPM1 | 312 (100) | 103 (100) | 85 (100) | 265 (100) | 105 (100) | ||||||
| Positive | 34 (11) | 13 (13) | 7 (8) | 50 (19) | 28 (27) | <.001 | |||||
| Negative | 278 (89) | 90 (87) | 78 (92) | 215 (81) | 77 (73) | ||||||
| Therapeutic approach | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| IC | 294 (33) | 66 (32) | 69 (31) | 261 (52) | 74 (41) | <.001 | |||||
| Non-IC | 149 (17) | 35 (17) | 25 (11) | 68 (14) | 25 (14) | ||||||
| HMA | 127 (14) | 27 (13) | 35 (15) | 51 (10) | 18 (10) | ||||||
| Clinical trial | 35 (4) | 11 (5) | 9 (4) | 14 (3) | 7 (4) | ||||||
| BSC | 234 (26) | 50 (24) | 70 (31) | 83 (17) | 44 (25) | ||||||
| Not available | 45 (5) | 20 (10) | 18 (8) | 25 (5) | 11 (6) | ||||||
| Characteristic . | MDS-AML . | MDS/MPN-AML . | MPN-AML . | t-AML . | neo-AML . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | ||
| Global | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Age, y | 70 (19-97) | 883 (100) | 69 (31-92) | 208 (100) | 68 (31-92) | 225 (100) | 67 (18-104) | 502 (100) | 73 (26-93) | 179 (100) | <.001* |
| Gender | 882 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Male | 548 (62) | 148 (71) | 129 (57) | 248 (49) | 121 (68) | <.001 | |||||
| Female | 334 (38) | 61 (29) | 97 (43) | 254 (51) | 58 (32) | ||||||
| ECOG | 1 (0-4) | 670 (100) | 1 (0-4) | 165 (100) | 1 (0-4) | 188 (100) | 1 (0-4) | 435 (100) | 1 (0-4) | 169 (100) | <.001* |
| 0 | 185 (28) | 34 (21) | 39 (21) | 130 (30) | 40 (24) | <.001 | |||||
| 1 | 268 (40) | 62 (38) | 73 (39) | 178 (41) | 64 (38) | ||||||
| 2 | 139 (21) | 36 (22) | 35 (19) | 80 (18) | 44 (26) | ||||||
| 3 | 67 (10) | 25 (15) | 27 (14) | 38 (9) | 18 (11) | ||||||
| 4 | 11 (2) | 8 (5) | 14 (7) | 9 (2) | 3 (2) | ||||||
| FAB subtype | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| M0/M6/M7 | 80 (9) | 4 (2) | 42 (19) | 65 (13) | 22 (12) | <.001 | |||||
| M1/M2 | 230 (26) | 18 (9) | 30 (13) | 118 (24) | 51 (28) | ||||||
| M4/M5 | 100 (11) | 79 (38) | 15 (7) | 121 (24) | 54 (30) | ||||||
| Not available | 474 (54) | 108 (52) | 139 (61) | 198 (39) | 52 (29) | ||||||
| Hepatosplenomegaly | 419 (100) | 114 (100) | 112 (100) | 290 (100) | 142 (100) | <.001 | |||||
| Yes | 77 (18) | 37 (32) | 44 (39) | 52 (18) | 24 (17) | ||||||
| No | 342 (82) | 77 (68) | 68 (61) | 238 (82) | 118 (83) | ||||||
| WBC, ×109/L | 4.4 (0.1-310.4) | 786 (100) | 23.5 (0.1-300.2) | 169 (100) | 10.8 (0.3-312) | 198 (100) | 5.1 (0.1-289) | 466 (100) | 10.7 (0.-230.7) | 173 (100) | <.001* |
| Hemoglobin, g/dL | 8.9 (3.3-17.2) | 690 (100) | 9.1 (4-15.1) | 154 (100) | 8.7 (4.7-15) | 173 (100) | 9.1 (3.2-15.2) | 452 (100) | 9.1 (4.4-14.4) | 170 (100) | .23* |
| Platelet count, ×109/L | 45 (1-1645) | 691 (100) | 55 (6-459) | 155 (100) | 74 (1-1372) | 173 (100) | 47 (2-1442) | 456 (100) | 58 (5-462) | 171 (100) | <.001* |
| BM blasts, % | 36 (2-100) | 653 (100) | 40 (1-100) | 136 (100) | 35 (0-94) | 148 (100) | 55 (0-100) | 408 (100) | 58 (10-100) | 160 (100) | <.001* |
| Creatinine, mg/dL | 0.97 (0.32-9.2) | 500 (100) | 1.07 (0.29-7.2) | 133 (100) | 0.95 (0.25-5.09) | 141 (100) | 0.9 (0.07-5.48) | 416 (100) | 0.97 (0.4-8.5) | 163 (100) | <.001* |
| Urea, mg/dL | 38 (4-192) | 456 (100) | 44 (11-255) | 121 (100) | 39 (8-242) | 126 (100) | 35 (2-243) | 391 (100) | 41 (11-267) | 146 (100) | <.001* |
| Uric acid, mg/dL | 5 (0.1-19) | 413 (100) | 6.5 (0.1-17.1) | 119 (100) | 5.8 (0-16.2) | 121 (100) | 4.9 (0-14.4) | 366 (100) | 5.3 (0-13) | 143 (100) | <.001* |
| Bilirubin, mg/dL | 0.7 (0.14-7.5) | 449 (100) | 0.75 (0.22-7) | 127 (100) | 0.67 (0.2-5.5) | 137 (100) | 0.64 (0.07-9.94) | 392 (100) | 0.62 (0.1-4.57) | 151 (100) | .06* |
| AST, U/L | 22 (7-171) | 451 (100) | 22 (6-496) | 119 (100) | 23 (8-151) | 124 (100) | 22 (5-213) | 383 (100) | 21 (8-338) | 150 (100) | .81* |
| ALT, U/L | 18 (2-272) | 461 (100) | 16 (3-515) | 121 (100) | 18 (3-160) | 131 (100) | 20 (3-623) | 395 (100) | 19 (5-328) | 152 (100) | .24* |
| AP, U/L | 78 (29-702) | 412 (100) | 82 (14-1158) | 115 (100) | 80 (26-1525) | 120 (100) | 77 (19-3571) | 354 (100) | 75 (2-3402) | 143 (100) | .41* |
| Albumin, g/dL | 3.7 (2.1-7) | 389 (100) | 3.7 (1.7-5.8) | 113 (100) | 3.7 (1.9-5.2) | 117 (100) | 3.7 (1.8-5.8) | 340 (100) | 3.7 (2.6-4.9) | 136 (100) | .95* |
| LDH, U/L | 416 (13-9168) | 571 (100) | 612 (96-11380) | 138 (100) | 768 (102-10560) | 147 (100) | 436 (12-9540) | 398 (100) | 561 (112-13420) | 149 (100) | <.001* |
| Fibrinogen, mg/dL | 423 (1-1033) | 358 (100) | 410 (1-940) | 111 (100) | 467 (3-889) | 115 (100) | 422 (3-983) | 328 (100) | 444 (2-1500) | 137 (100) | .04* |
| Cytogenetics | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| Normal | 247 (28) | 61 (29) | 49 (22) | 107 (21) | 60 (34) | <.001 | |||||
| Abnormal | 361 (41) | 72 (34) | 102 (45) | 266 (53) | 74 (41) | ||||||
| No metaphases | 65 (7) | 10 (5) | 12 (5) | 45 (9) | 14 (8) | ||||||
| Not available | 211 (24) | 66 (32) | 63 (28) | 84 (17) | 31 (17) | ||||||
| MRC cytogenetic risk | 612 (100) | 134 (100) | 152 (100) | 382 (100) | 137 (100) | ||||||
| Favorable | 4 (1) | 1 (1) | 2 (1) | 31 (8) | 11 (8) | <.001 | |||||
| Intermediate | 377 (62) | 94 (70) | 64 (42) | 172 (45) | 88 (64) | ||||||
| Adverse | 231 (38) | 38 (28) | 86 (57) | 179 (47) | 38 (28) | ||||||
| FLT3-ITD | 340 (100) | 104 (100) | 86 (100) | 288 (100) | 114 (100) | ||||||
| Positive | 35 (10) | 11 (11) | 3 (3) | 26 (9) | 24 (21) | <.001 | |||||
| Negative | 305 (90) | 93 (89) | 83 (97) | 262 (91) | 90 (79) | ||||||
| NPM1 | 312 (100) | 103 (100) | 85 (100) | 265 (100) | 105 (100) | ||||||
| Positive | 34 (11) | 13 (13) | 7 (8) | 50 (19) | 28 (27) | <.001 | |||||
| Negative | 278 (89) | 90 (87) | 78 (92) | 215 (81) | 77 (73) | ||||||
| Therapeutic approach | 884 (100) | 209 (100) | 226 (100) | 502 (100) | 179 (100) | ||||||
| IC | 294 (33) | 66 (32) | 69 (31) | 261 (52) | 74 (41) | <.001 | |||||
| Non-IC | 149 (17) | 35 (17) | 25 (11) | 68 (14) | 25 (14) | ||||||
| HMA | 127 (14) | 27 (13) | 35 (15) | 51 (10) | 18 (10) | ||||||
| Clinical trial | 35 (4) | 11 (5) | 9 (4) | 14 (3) | 7 (4) | ||||||
| BSC | 234 (26) | 50 (24) | 70 (31) | 83 (17) | 44 (25) | ||||||
| Not available | 45 (5) | 20 (10) | 18 (8) | 25 (5) | 11 (6) | ||||||
The type of sAML was not available in 310 patients.
P compare continuous variables.